Search Results

You are looking at 101 - 110 of 190 items for :

  • "Renal cell carcinoma" x
  • Refine by Access: All x
Clear All
Full access

NCCN Task Force Report: mTOR Inhibition in Solid Tumors

Robert A. Figlin, Elizabeth Brown, Andrew J. Armstrong, Wallace Akerley, Al B. Benson III, Harold J. Burstein, David S. Ettinger, Phillip G. Febbo, Matthew G. Fury, Gary R. Hudes, Merrill S. Kies, Eunice L. Kwak, Robert J. Morgan Jr., Joanne Mortimer, Karen Reckamp, Alan P. Venook, Frank Worden, and Yun Yen

of more than 1.5 times the upper limit of the normal range Hemoglobin level below the lower limit of the normal range A corrected serum calcium level of more than 10 mg/dL (2.5 mmol/L) Less than 1 year from initial diagnosis of renal cell carcinoma to

Full access


Localized Renal Cell Carcinoma Alpa Nick, MD, The University of Texas MD Anderson Cancer Center, Matched Pair Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination with Chemotherapy in Frontline Ovarian Cancer The awardees responded to

Full access


with Bortezomib in Previously Untreated Patients with Waldenström Macroglobulinemia.” Pazopanib is currently approved by the FDA to treat patients with advanced renal cell carcinoma. The research grant to NCCN will evaluate the effectiveness of

Full access

Next-Generation Sequencing and In Silico Analysis Facilitate Prolonged Response to Pazopanib in a Patient With Metastatic Urothelial Carcinoma of the Renal Pelvis

Andrew W. Hahn, Smith Giri, Dilan Patel, Heather Sluder, Ari Vanderwalde, and Mike G. Martin

metastatic renal cell carcinoma and soft tissue sarcoma. 22 The results of 3 small clinical trials evaluating pazopanib in the treatment of metastatic UC are summarized in Table 2 . 23 – 25 The contrasting results of the trials evaluating pazopanib alone

Full access

Central Nervous System Cancers, Version 2.2014

Louis Burt Nabors, Jana Portnow, Mario Ammirati, Henry Brem, Paul Brown, Nicholas Butowski, Marc C. Chamberlain, Lisa M. DeAngelis, Robert A. Fenstermaker, Allan Friedman, Mark R. Gilbert, Jona Hattangadi-Gluth, Deneen Hesser, Matthias Holdhoff, Larry Junck, Ronald Lawson, Jay S. Loeffler, Paul L. Moots, Maciej M. Mrugala, Herbert B. Newton, Jeffrey J. Raizer, Lawrence Recht, Nicole Shonka, Dennis C. Shrieve, Allen K. Sills Jr, Lode J. Swinnen, David Tran, Nam Tran, Frank D. Vrionis, Patrick Yung Wen, Nicole R. McMillian, and Maria Ho

from SRS regardless of the number of brain metastases present. 10 , 11 Some brain metastases of radioresistant primary tumors, such as melanoma and renal cell carcinoma, have also been shown to achieve good local control with SRS. 12 Other predictors

Full access

A Prospective Analysis of Plasma Adiponectin and Risk of Incident Cancer: The Dallas Heart Study

Muhammad Shaalan Beg, Sadia Saleem, Aslan Turer, Colby Ayers, James A. de Lemos, Amit Khera, Philipp E. Scherer, and Susan G. Lakoski

. 17. Liao LM Weinstein SJ Pollak M . Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers . Carcinogenesis 2013 ; 34 : 109 – 112 . 18. Aleksandrova K Boeing H Nothlings U . Inflammatory

Full access

Novel Non-Cytotoxic Therapy in Ovarian Cancer: Current Status and Future Prospects

Lainie Martin and Russell J. Schilder

): 455s . Abstract 5000 . 25. Hainsworth JD Sosman JA Spigel DR . Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib . J Clin Oncol 2005 ; 23 : 7889 – 7896 . 26. Herbst RS Johnson DH

Full access

Physician Awareness of Immune-Related Adverse Events of Immune Checkpoint Inhibitors

Ahmed Bilal Khalid, Gerardo Calderon, Shadia I. Jalal, and Greg A. Durm

clinical practice in a variety of cancers, including renal cell carcinoma 11 and non–small cell lung cancer. 12 More recently, the inhibition of additional targets such as LAG-3 have led to the approval of novel dual-immunotherapy combination treatments

Full access

PTCH1 Mutation in a Patient With Metastatic Undifferentiated Carcinoma With Clear Cell Change

Katy K. Tsai, Neharika Khurana, Timothy McCalmont, Adil Daud, Boris Bastian, and Iwei Yeh

off-label use of mTOR inhibitors currently approved for other indications (eg, everolimus in renal cell carcinoma, pancreatic neuroendocrine tumors, and breast cancer; temsirolimus in renal cell carcinoma) may have been a viable option. The splice site

Full access

Abstracts From the NCCN 2024 Annual Conference

Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial Chad Tang, MD 1 ; Kieko Hara, MD 1 ; Alexander D. Sherry, MD 1 ; Alejandra G. Serrano, MD 1 ; Larisa V. Kostousov, MS 1 ; Sharia D. Hernandez, MD 1 ; Wei Lu, MD